Cite
HLA ligandomics identifies histone deacetylase 1 as target for ovarian cancer immunotherapy.
MLA
Peper, Janet Kerstin, et al. “HLA Ligandomics Identifies Histone Deacetylase 1 as Target for Ovarian Cancer Immunotherapy.” Oncoimmunology, vol. 5, no. 5, July 2015, p. e1065369. EBSCOhost, https://doi.org/10.1080/2162402X.2015.1065369.
APA
Peper, J. K., Bösmüller, H.-C., Schuster, H., Gückel, B., Hörzer, H., Roehle, K., Schäfer, R., Wagner, P., Rammensee, H.-G., Stevanović, S., Fend, F., & Staebler, A. (2015). HLA ligandomics identifies histone deacetylase 1 as target for ovarian cancer immunotherapy. Oncoimmunology, 5(5), e1065369. https://doi.org/10.1080/2162402X.2015.1065369
Chicago
Peper, Janet Kerstin, Hans-Christian Bösmüller, Heiko Schuster, Brigitte Gückel, Helen Hörzer, Kevin Roehle, Richard Schäfer, et al. 2015. “HLA Ligandomics Identifies Histone Deacetylase 1 as Target for Ovarian Cancer Immunotherapy.” Oncoimmunology 5 (5): e1065369. doi:10.1080/2162402X.2015.1065369.